SWOG clinical trial number
CTSU/EAE161

Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Open
Phase
Abbreviated Title
Perfusion CT to Predict PFS and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status Notes
SWOG Activated/Championed CTSU/EAE161, effective March 1, 2019
Activated
03/01/2019
Participants
CTSU

Research committees

Early Therapeutics & Rare Cancers

Treatment

Olaparib

Eligibility Criteria Expand/Collapse

Please see the CTSU/EAE161 protocol posted on www.ctsu.org for eligibility criteria.

Other Clinical Trials

SWOG Clinical Trial Number
S0322

Single Agent ZD-1839 in Patients With Advanced Head and Neck Carcinoma or Non-Small Cell Lung Cancer Aged 75 Years and Older (and in a Cohort of Patients 50 Years Old and Younger), Pharmacology.

Research Committee(s)
Early Therapeutics & Rare Cancers
Head and Neck Cancer
Lung Cancer
Activated
08/15/2003
Closed
02/15/2005
Accrual
25%
Closed
Phase
I
SWOG Clinical Trial Number
S0355

A Phase I Pharmacokinetic Study of Epothilone B Analogue BMS-247550 (NSC-710428D) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction.

Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
11/01/2003
Closed
08/15/2006
Accrual
100%
Closed
Phase
I
Published
SWOG Clinical Trial Number
S0528

Phase I Study Evaluating the Combination of Lapatinib (GW572016; NSC-727989; IND-75,093) and Everolimus (RAD001; NSC-733504; IND-75,093) in Patients with Advanced Solid Tumors

Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
09/01/2006
Closed
08/25/2009
Accrual
100%
Closed
Phase
I
Published